GRACE :: Lung Cancer

Shirish Gadgeel

Denise Brock

Targeted Therapies Patient Forum September 2017 Speaker Highlight – Shirish M. Gadgeel, MD

Share

***Speaker Highlights***

for full faculty bio’s, please visit our FACULTY page


 Learn about Shirish M. Gadgeel, MD

 

Dr. Shirish Gadgeel is Co-Leader of the Thoracic Oncology Team in the Comprehensive Cancer Center at Michigan Medicine at the University of Michigan as of May 2017. He also has been appointed Associate Director for Cancer Care (ADCC) at Networking and Affiliated Centers.

Prior to joining Michigan Medicine Dr. Gadgeel was the co-leader of the Molecular Therapeutics Program of the Karmanos Cancer Institute (KCI).

Dr. Gadgeel has conducted and participated in many lung cancer specific trials and has also been a principal investigator of a Southwest Oncology Group trial, S0528 and NCI protocol 7389. He has engaged in many epidemiologic studies in the field of lung cancer, publishing on features of lung cancer in African-Americans and young patients. He is currently the principal investigator of multi-PI R21 to identify ‘driver’ genetic alterations in African-American lung cancer patients.  


Here is the first part of Dr. Gadgeel’s discussion from last year’s Targeted Therapies Patient Forum in Aurora, Colorado.  

 

Please feel free to offer comments and raise questions in our Discussion Forums.


Targeted Therapies in Lung Cancer Patient Forum

September 16, 2017

Presented by the Global Resource for Advancing Cancer Education in collaboration
with the Cleveland Clinic Cancer Center

See below for our growing list of topics and presenters!  

Register at cancerGRACE.org | Agenda is subject to change

8:30 – 10:00 am        The Many Faces of Progression
Dr. Nathan Pennell Cleveland Clinic Cancer Center The Role of Local Therapy
Dr. Shirish Gadgeel Karmanos Cancer Center, Wayne State University Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope
10:30 – noon       
The Question of Clinical Trials
Dr. Alice Shaw Massachusetts General Hospital The Crossroads: Local Therapy, Chemo, Targeted Therapy, or Immunotherapy? 
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients Matt Hiznay (ALK) and Sara Whitlock (RET). Moderator: Dr. H. (Jack) West

BREAKOUT SESSIONS

1:00 – 2:30 pm     
 
Presentations by Lung Cancer Sub-type
*Available treatment options 
*Acquired resistance: How do you pick your next treatment? 
ALK/ROS Dr. Alice Shaw, Dr. Shirish Gadgeel, & Matt Hiznay, ALK patient
EGFR Dr. Nathan Pennell, Dr. H. (Jack) West, & John Cherol, EGFR patient
MET/RET/BRAF Dr. Karen Reckamp, Dr. Vamsidhar Velcheti (Cleveland Clinic Cancer Center), & Sara Whitlock, RET patient

BREAKOUT SESSIONS

2:50 – 4:00 pm     
 
Managing the Costs of Cancer Care
James P. Stevenson, MD Cleveland Clinic Cancer Center
Patient to Patient Mentoring
Kathryn Sefcek, MHA 4th Angel Mentoring Program
Avoiding Fake News & Finding Trustworthy Cancer Info Online
Dr. H. (Jack) West Swedish Cancer Institute & Founder of cancerGRACE
Janet Freeman-Daily ROS1 patient, #LCSM Twitter Chat co-moderator, Cure Today contributor, Gray Connections blogger

 Please feel free to offer comments and raise questions in our Discussion Forums.

 GRACE would like to thank the following companies for their support of this forum:

B-I for web           
Guardant

 

 


Ask Us, Q&A
Lung/Thoracic Cancer Expert Content

Archives

Share

GRACE Cancer Video Library - Lung Cancer Videos

 

2015_Immunotherapy_Forum_Videos

 

2015 Acquired Resistance in Lung Cancer Patient Forum Videos

Share

Join the GRACE Faculty

Breast Cancer Blog
Pancreatic Cancer Blog
Kidney Cancer Blog
Bladder Cancer Blog
Head/Neck Cancer Blog
Share

Subscribe to the GRACEcast Podcast on iTunes

Share

Email Newsletter icon, E-mail Newsletter icon, Email List icon, E-mail List icon

Subscribe to
GRACE Notes
   (Free Newsletter)

Other Resources

Share

ClinicalTrials.gov


Biomedical Learning Institute

peerview_institute_logo_243